Related Experiment Videos

Platelet hyper- and hypoaggregability in different microangiopathic complications of diabetes mellitus

P Szénási1, L Tóth, L Romics

  • 1Semmelweis Orvostudományi Egyetem, III. Belgyógyászati Klinika, Budapest, Hungary.

Acta Diabetologica Latina
|January 1, 1988
PubMed

Insights

Diabetic nephropathy is linked to reduced platelet reactivity in vitro, despite evidence of increased platelet activity in vivo. Further research is needed to reconcile these findings in diabetes mellitus patients.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Diabetes mellitus is associated with vascular complications.
  • Platelet function is implicated in diabetic microvascular and macrovascular disease.
  • Contradictory findings exist regarding platelet hyper- or hypo-reactivity in diabetes.

Purpose of the Study:

  • To investigate in vitro platelet aggregometry in patients with diabetes mellitus and its complications.
  • To compare platelet responses to various agonists in diabetic patients with and without nephropathy, neuropathy, and retinopathy.
  • To determine if platelet reactivity differs based on diabetes type or azotemia presence.

Main Methods:

  • In vitro platelet aggregometry was conducted on 201 patients with diabetes mellitus and 106 controls.
  • Platelet aggregation was measured in response to collagen, arachidonic acid, epinephrine, and adenosine diphosphate.
  • Patients were stratified based on the presence of diabetic complications like nephropathy, neuropathy, and retinopathy.

Main Results:

  • Patients without complications and those with retinopathy showed hyperaggregability to certain agonists.
  • Platelet responses to all four stimuli were diminished in patients with diabetic nephropathy (with or without azotemia) compared to controls.
  • These altered platelet characteristics were independent of diabetes type.

Conclusions:

  • Diabetic nephropathy is characterized by reduced in vitro platelet reactivity (hypoaggregability).
  • This contrasts with established in vivo evidence of platelet hyperfunction in diabetes.
  • Further investigation is required to elucidate the mechanisms behind this in vitro hypoaggregability in nephropathic diabetic patients.

Related Concept Videos